Drug therapy + standard treatment adds value in prostate cancer?

    loading  Checking for direct PDF access through Ovid

Abstract

Prostate cancer is a prevalent and costly disease in the US, and the most common cancer among men. Non-surgical therapy frequently consists of androgen deprivation therapy (ADT) or radiation treatment combined with hormonal therapy. A study conducted in the US and presented at the 9th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) [Arlington, Virginia, US; May 2004] revealed that the addition of hormonal therapy to a regimen of radiation treatment was cost effective in patients with locally-advanced prostate cancer.1 A second US-based study presented at the conference contends that although the risk of osteoporotic fracture associated with ADT could be reduced by the addition of bisphosphonate therapy, the extra benefit may not be worth the additional cost.2

Related Topics

    loading  Loading Related Articles